Forging ahead with its new three-year business plan, Chugai Pharmaceutical enjoyed rosy earnings in the first half of 2019, bolstered by the outperformance of the Hemlibra (emicizumab) hemophilia drug and its I/O star Tecentriq (atezolizumab). But with a biosimilar onslaught…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Oncolys, Chugai Ink 50 Billion Yen Licensing Pact for Telomelysin
April 9, 2019
-
BUSINESS Novartis’ Eylea Challenger Could Reach Filing This Year for 2020 Launch
April 8, 2019
-
REGULATORY Japan’s 1st Avastin Biosimilar Could Get Listing as Early as November; Lilly’s EGFR Up for MHLW Panel Review
April 8, 2019
-
INTERVIEW With 90% Premium Cut, Japanese CEA Scheme Goes Beyond Its Purpose of Being “Complementary” Tool: FPMAJ Pricing Chief
April 5, 2019
-
BUSINESS Lilly Japan Nets 263 Billion Yen in 2018, Now 6th in Sales Ranking
April 4, 2019
-
BUSINESS Cefazolin Generic Shortage Raises Worries of Supply Crunch after G1 LLP Withdrawals
April 4, 2019
-
INTERVIEW Ex-Minister Tamura: 3 New Sources of Social Security Funding Needed to Stem Overreliance on Drug Price Cuts
April 3, 2019
-
COMMENTARY Building Credible, Convincing System Holds Key for Japan’s Cost-Effectiveness Assessment
April 2, 2019
-
REGULATORY MHLW Reveals Details of New Withdrawal Rules for Off-Patent Branded Drugs
April 1, 2019
-
BUSINESS Daiichi Sankyo Bags US$6.9 Billion AstraZeneca Pact for Cancer Hopeful DS-8201, Announces CEO Change
April 1, 2019
-
INTERVIEW Kyokai Kenpo Director Yoshimori: Japan Should Eventually Use Cost-Effectiveness Assessment to Set Launch Prices
March 29, 2019
-
BUSINESS Sumitomo Dainippon Carves Out Pain Program, 2025 Launch Eyed for Rare Pediatric Disease
March 29, 2019
-
REGULATORY Opdivo Up for Yet Another Re-Pricing after CEA Confirmatory Analysis, but New Price Undisclosed
March 28, 2019
-
REGULATORY National Cancer Center’s Fujiwara Named New PMDA Chief
March 27, 2019
-
BUSINESS Kymriah OK’ed, Novartis Says It’s Not Up for Outcome-Based Pricing in Japan
March 27, 2019
-
BUSINESS Novartis Snags Japan Approval for CAR-T Therapy Kymriah
March 26, 2019
-
REGULATORY Nesp Biosame Likely to Be Priced at 70% of Originator as Stopgap Measure
March 26, 2019
-
INTERVIEW With HIV Back in Hand, Gilead Heading into Second Phase in Japan Market: Pres. Hermans
March 26, 2019
-
REGULATORY PMDA Chief Kondo to Step Down after 11 Years in Charge
March 25, 2019
-
REGULATORY LDP Lawmakers Not So Positive about Reflecting Societal Values to Drug Prices; They Don’t Know How
March 22, 2019
ページ
Generic drug makers are making greater efforts to disclose more information on their products after years of repeated requests from doctors and medical institutions, which want to better ascertain their quality and stability of their supplies.Ohara Pharmaceutical has been disclosing…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In 2011 the Japanese pharmaceutical industry was rocked when a whistleblower exposed the falsification of trial data for the drug Diovan, the blockbuster blood pressure drug manufactured by pharma giant Novartis. The ensuing investigation led to the arrest of one…